$34.70
0.86% yesterday
Nasdaq, Aug 11, 10:00 pm CET
ISIN
US76155X1000
Symbol
RVMD

Revolution Medicines Inc Stock price

$34.70
-3.32 8.73% 1M
-6.75 16.28% 6M
-9.04 20.67% YTD
-8.28 19.26% 1Y
+11.20 47.66% 3Y
+6.67 23.80% 5Y
+5.80 20.07% 10Y
+5.80 20.07% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.30 0.86%
ISIN
US76155X1000
Symbol
RVMD
Industry

Key metrics

Basic
Market capitalization
$6.5b
Enterprise Value
$4.4b
Net debt
positive
Cash
$2.1b
Shares outstanding
186.9m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | 759.6
EV/Sales
- | 511.5
EV/FCF
negative
P/B
3.5
Financial Health
Equity Ratio
88.5%
Return on Equity
-26.5%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $8.6m
EBITDA
- | $-998.1m
EBIT
- | $-955.6m
Net Income
- | $-871.2m
Free Cash Flow
$-700.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -47.3%
EBIT
- | -38.6%
Net Income
- | -45.2%
Free Cash Flow
-34.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -11,588.7%
EBIT
-
Net
- | -10,115.1%
Free Cash Flow
-
More
EPS
-
FCF per Share
$-3.7
Short interest
7.8%
Employees
534
Rev per Employee
$0.0
Show more

Is Revolution Medicines Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Revolution Medicines Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Revolution Medicines Inc forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a Revolution Medicines Inc forecast:

Buy
95%
Hold
5%

Financial data from Revolution Medicines Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 97 97
28% 28%
-
- Research and Development Expense 593 593
40% 40%
-
-681 -681
41% 41%
-
- Depreciation and Amortization 12 12
93% 93%
-
EBIT (Operating Income) EBIT -692 -692
42% 42%
-
Net Profit -600 -600
38% 38%
-

In millions USD.

Don't miss a Thing! We will send you all news about Revolution Medicines Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Revolution Medicines Inc Stock News

Neutral
Seeking Alpha
5 days ago
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Anthony Mancini - Chief Global Commercialization Officer Jack Anders - Chief Financial Officer Mark A. Goldsmith - CEO, President & Chairman Ryan Asay - Senior Vice President of Corporate Affairs Stephen M.
Neutral
GlobeNewsWire
5 days ago
REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2025, and provided an update on corporate progress.
Neutral
GlobeNewsWire
12 days ago
REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter of 2025 on Wednesday, August 6, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Re...
More Revolution Medicines Inc News

Company Profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company's principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors. The company was founded in 2014 and is headquartered in Redwood City, California.

Head office United States
CEO Mark Goldsmith
Employees 534
Founded 2004
Website www.revmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today